Cataract Surgery in America
Cataract surgery is the single most commonly performed surgical procedure in the United States today — and one of the most successful. A cataract develops when the natural lens of the eye becomes progressively cloudy, causing blurred vision, sensitivity to glare, faded colors, and eventually severe vision loss or blindness if left untreated. The surgery itself, known as phacoemulsification, involves making a tiny incision in the eye, using ultrasound energy to break up the clouded lens, removing it, and inserting a clear artificial intraocular lens (IOL) in its place. The entire procedure typically takes less than 30 minutes and is almost always performed on an outpatient basis, meaning patients go home the same day. With an estimated 3.8 to 4.2 million cataract surgeries performed annually in the United States — a number growing at 3–4% per year — this is a procedure that touches the lives of millions of Americans every single year.
What makes cataract surgery in America in 2026 especially significant is the convergence of demographic pressure, technological advancement, and expanding access. The US population over age 65 is the largest it has ever been, and cataracts are overwhelmingly an age-related condition — more than 50% of Americans aged 80 or older have cataracts or have already undergone cataract surgery. At the same time, the emergence of femtosecond laser-assisted cataract surgery (FLACS), next-generation premium intraocular lenses, and the rise of office-based surgery (OBS) settings are rapidly transforming both the patient experience and clinical outcomes. For patients, caregivers, healthcare providers, and policymakers alike, understanding the latest cataract surgery statistics for 2026 is essential to navigating one of America’s most critical — and most performed — medical procedures.
Interesting Facts About Cataract Surgery in the US 2026
CATARACT SURGERY FAST FACTS — US 2026
========================================
Annual Surgeries (US) ████████████████████ ~3.8–4.2 Million
Overall Success Rate ████████████████████ ~95–98%
Outpatient Procedures ████████████████████ ~91%
ASC Setting Share ██████████████ ~71–91%
Female Patients ████████████ ~58–61%
Americans w/ Cataracts ████████████████████ 25+ Million
Adults 80+ w/ Cataracts ████████████████████ 50%+
Medicare Covers ████████████████ 80% (after deductible)
Scale: Each █ ≈ ~5 percentage points or proportional units
| Fact | Statistic / Detail |
|---|---|
| Annual cataract surgeries performed in the US | Approximately 3.8 to 4.2 million per year and growing 3–4% annually |
| Projected US annual volume by 2030 | Expected to reach 6 million cataract surgeries per year |
| Americans affected by cataracts (age 40+) | 24.4 million Americans age 40+ (NEI); 25+ million total US adults |
| Projected cataract cases by 2032 | 38.5 million Americans projected to have cataracts by 2032 |
| Projected cataract cases by 2050 | 45.6 million — reflecting a near-doubling of current prevalence |
| Adults 80+ with cataracts | More than 50% of Americans aged 80 or older have cataracts or have had cataract surgery |
| Cataract prevalence in Medicare population (2021) | 37.03% of Medicare beneficiaries 65+ have cataracts (CDC VEHSS / ScienceDirect, 2025) |
| Overall surgery success rate | 95–98% — among the highest of any surgical procedure (ASCRS) |
| Patient functional improvement rate | 90% of first-eye cataract surgery patients report improved functional status and vision satisfaction (Cataract PORT study) |
| Outpatient / ASC setting share | 71–91% of US cataract surgeries performed in ambulatory surgery centers |
| Posterior capsule rupture rate | ~0.2% of cases (Medicare FFS claims study, Journal of Ophthalmology, 2022) |
| Periprosthetic infection rate | Exceptionally rare — <0.1% with modern antibiotic protocols |
| Premium IOL surgeon adoption (US) | 37% of US surgeons now use premium intraocular lenses |
| Foldable IOL usage | 82% of all US cataract procedures use foldable intraocular lenses |
| Medicare Part B deductible (2026) | $283 annual deductible; Medicare then covers 80% of approved costs |
| ASC national payment rate — routine cataract (2026) | Approximately $1,255 per procedure (CMS national payment rate) |
| Out-of-pocket cost without insurance | $3,000–$7,000 per eye depending on technique and lens type |
| Average out-of-pocket with Medicare (ASC, 2025) | Approximately $384 for extracapsular removal at ASC; $598 at hospital outpatient (Medicare.gov national data) |
| Cataract surgery procedure time | Typically less than 30 minutes per eye |
| Gender split — female patients | Women account for approximately 58–61% of cataract surgery patients |
Source: National Eye Institute (NEI); CDC Vision and Eye Health Surveillance System (VEHSS); CMS Medicare 2026 Payment Data; American Society of Cataract and Refractive Surgery (ASCRS); Journal of Ophthalmology Medicare Claims Study (2022); Nature/Eye journal — “The future of cataract surgery” (NIH/PMC, 2025)
The dominance of cataract surgery in the American healthcare landscape is undeniable. With 3.8 to 4.2 million procedures performed every year, it dwarfs every other surgical category in the US by sheer volume — and yet it carries a success rate of 95–98%, making it simultaneously the most common and one of the safest surgeries performed anywhere in the world. The underlying disease burden is immense: 24.4 million Americans age 40 and older already have cataracts according to the National Eye Institute, with projections from multiple epidemiological models estimating this will climb to 38.5 million by 2032 and 45.6 million by 2050. The fact that more than 50% of Americans aged 80 or older already have cataracts or have undergone surgery speaks volumes about just how age-linked this condition truly is.
From a clinical standpoint, what stands out most in the fact table above is the combination of extraordinary scale and extraordinary safety. A posterior capsule rupture rate of just 0.2% and an infection rate below 0.1% place cataract surgery in 2026 among the most technically reliable procedures in all of medicine. The shift toward premium IOL adoption — now embraced by 37% of US surgeons — reflects a system increasingly moving beyond simply restoring functional vision toward optimizing the quality of vision patients enjoy post-surgery. Meanwhile, the $283 Part B deductible and 80% Medicare coverage framework ensures that the majority of the over-65 population — precisely the demographic most affected by cataracts — has a financially accessible path to surgical care.
Cataract Surgery Volume & Projections in US 2026
US CATARACT SURGERY VOLUME — TRENDS & PROJECTIONS
====================================================
2006 |████████████████ ~3.1 Million (NCHS/CDC ambulatory data)
2018 |████████████████████ ~3.8 Million
2024 |████████████████████████ ~4.2 Million (est.)
2026 |█████████████████████████ ~4.4–4.5 Million (est.)
2030 |████████████████████████████████ ~6.0 Million (projected)
Annual growth rate: 3–4% per year
Scale: Each █ ≈ ~200,000 procedures
| Year / Period | Estimated Annual US Cataract Surgeries | Notes / Source |
|---|---|---|
| 2006 | ~3.1 million | NCHS CDC National Survey of Ambulatory Surgery (most frequent outpatient surgery) |
| ~2018 | ~3.8 million | iData Research; NIH/Eye journal confirmed figure |
| 2021–2022 | ~3.8 million | Nature/Eye (PMC, 2025): “approximately 3.8 million performed annually in the USA” |
| 2023–2024 | ~4.0–4.2 million | Market data; ~4.2M cited across 6,000+ hospitals and ASCs |
| 2026 (estimated) | ~4.4–4.5 million | At 3–4% annual growth trajectory |
| 2030 (projected) | ~6 million | iOR Partners projection based on demographic modeling |
| Medicare annual surgeries (plateau, ~2021) | ~1.4 million Medicare FFS cataract surgeries | ScienceDirect / CDC VEHSS Medicare data (2025) |
| Global cataract surgeries (2024) | 28 million+ globally | US accounts for a significant share of high-income nation volume |
| Annual ASC growth rate | 4.7–5.9% per year (2018–2024) | 6,052 ASCs in the US as of 2024 (IBIS World) |
Source: CDC National Center for Health Statistics (NCHS) National Survey of Ambulatory Surgery; iOR Partners demographic modeling; NIH/PMC — Nature Eye journal (2025); ScienceDirect / CDC VEHSS Medicare Cataract Study (2025)
Cataract surgery volume in the United States has been climbing steadily for decades, and the trajectory shows no signs of reversing. Even as recently as 2006, the CDC’s National Survey of Ambulatory Surgery identified cataract extraction as the single most frequently performed outpatient procedure in the country, with approximately 3.1 million surgeries at that time. By 2018, that figure had grown to roughly 3.8 million, and by 2024, estimates from multiple market and clinical research sources consistently point to a range of 4.0 to 4.2 million procedures annually. At the current 3–4% annual growth rate, the US is expected to reach approximately 6 million cataract surgeries per year by 2030 — a milestone that will place extraordinary demands on the nation’s ophthalmology workforce and surgical infrastructure.
The Medicare-specific data adds an important layer to this picture. Among Medicare fee-for-service beneficiaries alone, annual cataract surgeries plateaued at approximately 1.4 million procedures in recent tracked years — a figure that reflects the dominant role the Medicare program plays in financing this surgery for America’s older population. The parallel rise of ambulatory surgery centers, with 6,052 ASCs operating nationwide in 2024 and a sector growing at 4.7–5.9% per year, is the infrastructure story behind these volume numbers. With ASCs now handling the overwhelming majority of cataract procedures, the US surgical system has built remarkable capacity to absorb this growing patient population — though looming surgeon shortages and competition for operating room time from more lucrative procedures remain real structural concerns heading into 2026 and beyond.
Cataract Surgery Costs & Insurance Coverage in US 2026
CATARACT SURGERY COST BREAKDOWN — US 2026 (PER EYE)
=====================================================
Standard Phaco (no insurance) |█████████████ $1,000–$3,000
Full Package (no insurance) |████████████████ $3,000–$7,000
With Medicare (ASC, 2025) |█ ~$384 out-of-pocket
With Medicare (HOPD, 2025) |█ ~$598 out-of-pocket
Premium IOL upgrade (patient) |█████████ $1,500–$2,500+ extra
Multifocal IOL (premium) |████████████ $2,000–$4,000/eye
FLACS laser add-on |████ $1,500+ extra/eye
YAG capsulotomy (later, if needed) |█ $300–$500
Scale: Each █ ≈ ~$400
| Cost Category | Amount / Range (US 2026) | Notes |
|---|---|---|
| Standard cataract surgery (no insurance) | $3,000–$7,000 per eye | Includes surgeon, facility, anesthesia, standard IOL |
| AAO standard estimate (no insurance) | $2,000–$3,000 per eye | Basic procedure with standard monofocal IOL (AAO) |
| Average out-of-pocket cost estimate | ~$4,131 per eye | Most recent updated average (PMC/NIH economic review, Aug 2023 data) |
| Medicare Part B annual deductible (2026) | $283 | Paid once per year before Medicare covers its share |
| Medicare coverage after deductible | 80% of Medicare-approved amount | Patient pays remaining 20% |
| CMS national ASC payment rate (2026) | ~$1,255 per routine cataract surgery | CMS published national rate |
| Patient cost — extracapsular at ASC (2025) | ~$384 out-of-pocket | Medicare national average data (Medicare.gov) |
| Patient cost — extracapsular at HOPD (2025) | ~$598 out-of-pocket | Medicare national average data (Medicare.gov) |
| Standard monofocal IOL | Covered by Medicare/insurance | Basic single-focus distance lens |
| Premium multifocal IOL (patient pays extra) | $2,000–$4,000 per lens | Not covered by Medicare or most insurers |
| Toric IOL (astigmatism correction) | ~$1,500 per lens | Patient pays upgrade difference |
| Light-adjustable lens (LAL) | $5,500+ per eye | Post-operative adjustable; premium out-of-pocket |
| Femtosecond laser-assisted (FLACS) add-on | +$1,500 per eye minimum | Considered elective upgrade by insurers |
| YAG laser capsulotomy (secondary procedure) | $300–$500 without insurance | Needed in some cases 1–5 years after surgery |
| Post-operative eye drops | $100–$300 uninsured; less with Rx coverage | Generic/compounded options available |
| One pair of prescription eyeglasses post-surgery | Covered by Medicare (standard frames only) | After IOL implantation |
Source: CMS Centers for Medicare & Medicaid Services 2025–2026 Payment and Coverage Data; Medicare.gov 2025 national procedure cost data; American Academy of Ophthalmology (AAO); PMC/NIH Economic Evaluation of IOL study (2025)
Cataract surgery costs in the United States in 2026 span a wide range depending on insurance status, surgical technique, facility type, and lens selection. For the uninsured patient, the total per-eye cost can range from $3,000 to $7,000, with the most recent average out-of-pocket estimate for all-comers landing around $4,131 per eye based on compiled US data. However, the actual experience for most patients looks very different. The Medicare coverage framework — which covers 80% of approved costs after the $283 Part B deductible in 2026 — means that the typical Medicare beneficiary having standard cataract surgery at an ambulatory surgery center will pay only about $384 out-of-pocket per eye based on national Medicare data. That is a remarkably low cost for a procedure that can restore sight and fundamentally improve quality of life.
Where costs escalate significantly is in the realm of premium upgrades that Medicare and most private insurers do not cover. Multifocal IOLs, which allow patients to see at multiple distances and reduce dependence on reading glasses, add $2,000–$4,000 per lens to the bill. Toric IOLs for astigmatism correction add approximately $1,500 per lens. Light-adjustable lenses, which can be fine-tuned after surgery using ultraviolet light treatments, can exceed $5,500 per eye. And femtosecond laser-assisted cataract surgery (FLACS) adds at least $1,500 per eye compared to traditional phacoemulsification. For patients who want the best possible visual outcomes and maximum spectacle independence after their surgery, these premium options can push total costs to $10,000 or more per eye — an entirely out-of-pocket expense that is driving growing financial stratification in US cataract care in 2026.
Cataract Surgery Success Rates & Clinical Outcomes in US 2026
CATARACT SURGERY SUCCESS & COMPLICATION RATES — US 2026
=========================================================
Overall Success Rate ████████████████████ 95–98%
Patient Satisfaction (1st eye) ████████████████████ ~90%
Vision Improvement Sustained ████████████████████ 90%+ long-term
Posterior Capsule Rupture ▌ ~0.2%
IOL Exchange / Reposition ▌ ~0.2% / 0.2%
Periprosthetic Infection ▌ <0.1%
Nd:YAG Capsulotomy (6mo) ██ ~4.7% (secondary)
IOL 10-yr dislocation ▌ <0.1%
Scale: Each █ ≈ 5 percentage points; ▌ = <1%
| Outcome / Complication Metric | Rate / Statistic |
|---|---|
| Overall cataract surgery success rate | 95–98% (American Society of Cataract and Refractive Surgery, ASCRS) |
| Patient functional improvement — first eye | 90% of patients report improved functional status and vision satisfaction (Cataract Patient Outcomes Research Team / PORT) |
| Long-term vision improvement maintenance | Over 90% of patients maintain substantially improved vision years later, absent other eye disease |
| No adverse events — Medicare cohort (1994–2006) | 99.5% of 200,000 Medicare beneficiaries experienced no adverse side effects (ASCRS data) |
| Posterior capsule rupture rate (intraoperative) | ~0.2% of cases (Medicare FFS claims, Journal of Ophthalmology, 2022) |
| IOL exchange rate (<6 months) | ~0.2% (Medicare FFS claims analysis, 2022) |
| IOL repositioning rate (<6 months) | ~0.2% (Medicare FFS claims analysis, 2022) |
| Nd:YAG laser capsulotomy rate (<6 months) | 4.7% — most common secondary intervention (Medicare FFS data, 2022) |
| 10-year IOL dislocation rate | 0.1% or lower — IOL typically stable for life |
| Phacoemulsification intraoperative complication rate | ~6.6% (vs. ~16.55% for manual small-incision technique) |
| Good visual outcome (VA ≥ 6/18) — phaco | ~86% at one month post-op in comparative studies |
| Most common comorbidities in cataract patients | Diabetes (28.6%), glaucoma (22.1%), macular degeneration (21.7%) — Medicare FFS cohort |
| Average patient age in Medicare cataract cohort | 73.8 years |
| Cataract surgery setting — ASC share | 71.3% in ASC vs. 27.6% hospital outpatient department (Medicare FFS cohort data) |
| Median time between first and second eye surgeries | 15 days |
Source: American Society of Cataract and Refractive Surgery (ASCRS); Cataract Patient Outcomes Research Team (PORT) — MIPS Measure #303 (CMS, 2025); Journal of Ophthalmology — Real-World Cataract Surgery Complications (Medicare Claims, 2022); Mass Eye and Ear Ophthalmology Outcomes data
The clinical success rate of cataract surgery in the United States is, by any measure, extraordinary. The American Society of Cataract and Refractive Surgery estimates an overall success rate of 95–98%, and historical Medicare data covering 200,000 beneficiaries over more than a decade found that 99.5% experienced no adverse side effects. The Cataract Patient Outcomes Research Team confirms that 90% of patients undergoing first-eye surgery report meaningful improvements in functional status and satisfaction with their vision — numbers that place cataract surgery in 2026 firmly among the most consistently effective elective procedures in all of American medicine. When complications do occur, they are predominantly minor and manageable: the most common secondary intervention is the Nd:YAG laser capsulotomy — a simple outpatient procedure needed in approximately 4.7% of cases within six months when the posterior lens capsule becomes cloudy, commonly called a “secondary cataract.”
The comorbidity data from Medicare claims reveals an important dimension of cataract surgery demographics in the US. A striking 28.6% of cataract surgery patients have diabetes, 22.1% have glaucoma, and 21.7% have macular degeneration — conditions that can limit the achievable visual outcome even after technically successful surgery. This is why the 90%+ long-term vision improvement rate is best understood with the important caveat: patients who develop other ocular diseases such as age-related macular degeneration or diabetic retinopathy may find their vision quality limited by those conditions rather than by the cataract surgery itself. For otherwise healthy eyes, the IOL is designed to last a lifetime, with a 10-year dislocation rate below 0.1% and the vast majority of patients never needing any follow-up surgical intervention beyond the initial procedure.
Cataract Patient Demographics in US 2026
CATARACT PATIENT DEMOGRAPHICS — US 2026
=========================================
GENDER (Cataract Cases / Surgery Patients)
Female ████████████████████████ ~58–61%
Male ████████████████ ~39–42%
RACE — Cataract Prevalence by Age 80 (NEI Data)
White Americans ████████████████████████████ ~70%
Hispanic Americans ████████████████████████ ~61%
Black Americans █████████████████████ ~53%
AGE — Cataract Prevalence (US Adults 40+)
Ages 40–49 ██ ~2.5%
Ages 50–64 ████████ increasing markedly
Ages 65–74 ████████████████ ~37%+ (Medicare)
Ages 75+ ████████████████████ 50%+
Scale: Each █ ≈ ~5 percentage points
| Demographic Category | Statistic / Data Point |
|---|---|
| Female cataract patients | Women account for approximately 58.2–61% of cataract surgery patients |
| Male cataract patients | Men account for approximately 39–42% of cataract surgery patients |
| Female cataract prevalence (NEI) | 19.67% of women have cataracts (vs. 14.26% of men) — NEI data |
| Female share of cataract-related blindness | Women account for ~60% of cataract-related blindness cases globally |
| Average Medicare cataract patient age | 73.8 years — Medicare FFS cohort |
| Adults 75+ with cataracts (US) | ~50% of all Americans aged 75 and older |
| Adults 80+ with cataracts | More than 50% have cataracts or have had cataract surgery |
| Medicare beneficiaries 65+ with cataracts (2021) | 37.03% — up from 36.38% in 2014 (CDC VEHSS / ScienceDirect 2025) |
| White Americans — prevalence by age 80 | ~70% will have cataracts by age 80 (NEI data) |
| Hispanic Americans — prevalence by age 80 | ~61% will have cataracts by age 80 (NEI data) |
| Black Americans — prevalence by age 80 | ~53% will have cataracts by age 80 — lowest among major US racial groups (NEI data) |
| White Americans — prevalence by age 75 | At least 50% have cataracts by age 75 (NEI) |
| Cataract prevalence ages 40–49 | Only ~2.5% of Americans in this age group (NEI) |
| Medicare as primary payer | Medicare is the dominant payer — annual Medicare cataract surgeries ~1.4 million (VEHSS) |
| Bilateral cataracts | ~67.6% of cataract patients are affected bilaterally (comparative study data) |
| Median days between bilateral surgeries | 15 days between first and second eye surgery |
Source: National Eye Institute (NEI) age/race/gender prevalence data; CDC Vision and Eye Health Surveillance System (VEHSS); ScienceDirect — Medicare Cataract Study (2025); Journal of Ophthalmology Medicare FFS cohort analysis (2022)
The demographics of cataract surgery patients in America are as illuminating as they are predictable — this is, above all else, a disease and a surgery of aging. The Medicare FFS cohort data confirms an average patient age of 73.8 years, placing the overwhelming majority of cataract surgery recipients squarely in the population covered by Medicare, which explains why Medicare’s approximately 1.4 million annual cataract surgeries represent the largest single payer slice of procedure volume. Women dominate the patient population, accounting for approximately 58–61% of all cataract surgery patients, driven by both their higher lifetime cataract prevalence (19.67% of women vs. 14.26% of men per NEI data) and their longer life expectancy, which means more years of exposure to the aging process that leads to lens clouding. Among patients with cataracts, 67.6% are affected in both eyes, and the standard of care in 2026 is to perform surgery on the second eye approximately 15 days after the first.
The racial and ethnic data on cataract prevalence reveals an important and somewhat counterintuitive pattern: White Americans carry the highest risk of cataracts — approximately 70% will have cataracts by age 80 — while Black Americans have the lowest prevalence at approximately 53% by age 80, followed by Hispanic Americans at 61%. This is notably different from the racial disparity pattern seen in knee replacement surgery, where Black patients are underserved relative to their disease burden. In cataracts, the disparity is in prevalence rather than in access, though disparities in access to premium IOL options and advanced surgical techniques do exist along socioeconomic lines. The relentless march of the aging Baby Boomer population ensures that cataract prevalence — and cataract surgery demand — will continue to climb steeply through 2026 and well into the 2030s, with projections pointing to 38.5 million Americans affected by 2032.
Cataract Surgery Technology Trends in US 2026
CATARACT SURGERY TECHNOLOGY ADOPTION — US 2026
================================================
Phacoemulsification (standard) ████████████████████ ~82–88% of procedures
Foldable IOL usage ████████████████████ ~82% of all procedures
Premium IOL surgeon adoption ████████████ ~37% of US surgeons
FLACS (femtosecond laser) ████ Growing (est. 12–15%)
Advanced surgical platforms ████████████████ ~69% of operations
Office-Based Surgery (OBS) ████ Emerging/expanding
ASC setting share ████████████████████ ~71–91%
Scale: Each █ ≈ ~5 percentage points
| Technology / Setting Metric | Data / Statistic |
|---|---|
| Phacoemulsification — procedure share | Still the dominant standard; ~82% of global procedures; nearly universal in the US |
| Femtosecond laser-assisted (FLACS) global growth | Laser-assisted procedures grew 18% year-over-year; 3.4 million FLACS surgeries in 2024 globally |
| Femtosecond laser systems installed globally (2024) | 1,800 systems as of 2024, up from 1,400 in 2023 |
| Foldable IOL usage in US procedures | 82% of all US cataract procedures use foldable intraocular lenses |
| Advanced surgical platforms | Support 69% of all US cataract operations |
| Premium IOL surgeon adoption rate (US) | 37% of US ophthalmologists now implanting premium IOLs |
| Premium IOL uptake — global (2024) | 22% of all implants globally are premium IOLs; multifocal +14%, toric +11%, EDOF +7% |
| Ambulatory Surgery Center (ASC) share | 71.3% ASC (Medicare FFS data); up to 91% outpatient across all settings |
| Hospitals and ASCs performing cataract surgery (US) | 6,000+ facilities nationwide |
| Office-Based Surgery (OBS) — emerging trend | Over 60,000 ophthalmic OBS procedures already performed; growing as ASCs de-prioritize cataract |
| Multifocal IOL — spectacle independence rate | 86.0–90.9% spectacle independence vs. 8.5–31.8% for monofocal IOLs (PMC/NIH ICER analysis) |
| Multifocal IOL cost-effectiveness (US) | ICER of $4,805 per QALY vs. $50,000/QALY US threshold — highly cost-effective (NIH/PMC, 2025) |
| Miniaturized phaco machine adoption | Portable equipment reduced from 18 kg to 10–12 kg (2022–2024); enabling mobile surgical units |
| AI integration in cataract care | Emerging focus area — identified as key future direction in NIH/Eye Cambridge Symposium paper (2025) |
Source: NIH/PMC — “The future of cataract surgery” (Nature/Eye, 2025); PMC/NIH Economic Evaluation of IOL study (2025); CMS/Medicare facility data; iOR Partners OBS data 2024; Market Growth Reports cataract surgery market 2024
The technology landscape for cataract surgery in the United States in 2026 is undergoing its most significant transformation since the introduction of phacoemulsification itself. Phacoemulsification remains the gold standard, used in the vast majority of US cataract procedures — but it is increasingly being augmented or replaced in premium cases by femtosecond laser-assisted cataract surgery (FLACS), which uses a precisely controlled laser to automate the most technically demanding steps of the procedure, including the incision, anterior capsulotomy, and lens fragmentation. Globally, FLACS procedures grew 18% year-over-year in 2024, with 3.4 million laser-assisted surgeries performed and 1,800 femtosecond laser systems now installed in ophthalmic facilities worldwide — up from 1,400 just a year prior. In the US, 37% of ophthalmologists are now implanting premium intraocular lenses, and 82% of all procedures use foldable IOLs that allow insertion through a micro-incision.
The most consequential emerging structural trend is the rise of office-based surgery (OBS) as a response to a growing capacity crisis. More than four million cataract surgeries per year demand surgical time, but ambulatory surgery centers are increasingly deprioritizing cataract surgery in favor of more lucrative orthopedic and general surgery procedures. Over 60,000 ophthalmic OBS procedures have already been performed in physician office settings with safety outcomes matching or exceeding ASC benchmarks. Meanwhile, multifocal IOL technology continues to demonstrate compelling cost-effectiveness data — with a cost per quality-adjusted life year (QALY) of just $4,805 compared to the $50,000 per QALY US healthcare threshold — providing powerful economic justification for broader premium lens adoption even in cost-constrained healthcare systems. The integration of artificial intelligence for surgical planning, patient risk assessment, and IOL selection is identified in the 2025 NIH/Cambridge Ophthalmology Symposium paper as the next major frontier in cataract care.
Medicare & Economic Burden of Cataract Surgery in US 2026
MEDICARE ECONOMIC BURDEN — US CATARACT SURGERY
================================================
Medicare reimbursements 2014 ████████████████████ $1.015 Billion
Medicare reimbursements 2021 ████████████████ $741 Million
(Inflation-adjusted decline despite stable volume)
Per-surgery Medicare payment ███ ~$1,255 (ASC, 2026)
Surgeon fee (Medicare, avg) ██ Included in approved amt.
Annual Medicare FFS surgeries ████████████████████ ~1.4 Million/yr
Untreated cataract — econ. cost High (reduced productivity, falls, accidents)
Note: Total system cost includes direct and indirect costs
Scale: Each █ ≈ ~$63 million (reimbursement bars) or proportional
| Economic / Medicare Metric | Statistic / Data |
|---|---|
| Annual Medicare FFS cataract surgeries (plateau) | Approximately 1.4 million per year (CDC VEHSS / ScienceDirect Medicare study, 2025) |
| Inflation-adjusted Medicare reimbursements (2014) | $1.015 billion total for cataract surgery (Medicare FFS) |
| Inflation-adjusted Medicare reimbursements (2021) | $741 million — decreased despite stable surgical volume |
| Reimbursement decline 2014–2021 | ~27% decline in real-dollar Medicare cataract surgery reimbursements |
| CMS ASC national payment rate (2026) | ~$1,255 per routine cataract procedure |
| Medicare Part B deductible (2026) | $283 annual deductible (all Part B services) |
| Cataract prevalence trend (Medicare 65+) | Rose from 36.38% (2014) to 37.03% (2021) — steady upward trend (CDC VEHSS) |
| Black beneficiaries — surgical rates | Lowest surgical rates among racial groups in Medicare FFS cataract data |
| Untreated cataract — indirect costs | Reduced driving ability, falls, hip fractures, depression, cognitive decline risk |
| Global cataract surgery devices market (2024) | $8.91 billion (growing to $12.47 billion by 2033) |
| US cataract surgery market growth driver | Aging population + expanding premium IOL and laser technology adoption |
| Medigap — covers 20% coinsurance | Plans A, B, D, G, M, N cover remaining 20% coinsurance after deductible |
| Medicare Advantage — additional vision benefits | MA plans must cover cataract surgery at minimum; may offer extra vision benefits |
Source: ScienceDirect — “Prevalence, Surgical Trends, and Economic Burden of Cataract in Medicare Population in the United States” (2025); CMS Medicare 2026 Payment Data; CDC Vision and Eye Health Surveillance System (VEHSS); Global market data for cataract devices
The economic story of cataract surgery under Medicare is one of the most striking in all of American healthcare — a paradox of rising patient volume and falling per-procedure reimbursements. Between 2014 and 2021, inflation-adjusted Medicare reimbursements for cataract surgery fell from $1.015 billion to $741 million — a ~27% real-dollar decline — even as the annual procedure volume among Medicare beneficiaries held relatively steady at approximately 1.4 million surgeries per year. This decline reflects decades of progressive Medicare fee schedule reductions for cataract surgery, driven in part by improvements in surgical efficiency and in part by broader CMS payment reform efforts. The practical consequence is that the financial incentive for ophthalmologists to perform Medicare cataract surgery has steadily eroded, directly fueling the pivot toward premium private-pay upgrades like multifocal IOLs and FLACS, where surgeon and facility fees are not subject to Medicare rate schedules.
The economic burden of untreated cataracts — which are a significant concern among lower-income, uninsured, or access-limited populations — extends well beyond vision itself. Uncorrected vision impairment from cataracts is associated with increased fall and fracture risk, impaired driving ability, greater risk of depression and cognitive decline, and reduced workforce participation in those not yet at retirement age. The racial disparity within Medicare cataract data is particularly concerning: Black Medicare beneficiaries have the lowest surgical rates despite their substantial cataract burden — a finding consistent with broader patterns of healthcare underutilization documented across multiple studies. As the global cataract surgery devices market grows from $8.91 billion in 2024 to a projected $12.47 billion by 2033, the commercial ecosystem around this surgery is expanding — but ensuring equitable access to its benefits across all racial and socioeconomic groups remains the defining public health challenge for cataract care in the United States through 2026 and beyond.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.